Fierce Pharma
NOVEMBER 4, 2024
Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to launch its JAK inhibitor competitor to Eli Lilly and Incyte’s Olumiant and | Sun Pharma, which had been plotting a mid-October launch for its JAK inhibitor Leqselvi, has been slapped with in an injunction blocking the rollout of the alopecia areata drug.
pharmaphorum
NOVEMBER 4, 2024
Outlook Therapeutics' Lytenava is the first ophthalmic formulation of bevacizumab to be cleared for use by NICE for use in the NHS for wet AMD
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 4, 2024
As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against competitors.
MedCity News
NOVEMBER 4, 2024
I met a mix of biotech and healthtech companies at HLTH affecting everything from drug development, drug efficacy to controlling specialty care costs and managing chronic diseases. The post 5 Interesting Companies I Saw at HLTH appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
NOVEMBER 4, 2024
BioNTech reported surprisingly strong sales of its COVID-1 | BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter. Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2.5 billion to €3.1 billion.
pharmaphorum
NOVEMBER 4, 2024
Novo Nordisk puts $285m into a once-monthly GLP-1 agonist for obesity using technology developed by fellow Danish pharma Ascendis
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
NOVEMBER 4, 2024
Accord Healthcare unveils £50m investment, backed by the UK government, that will see a new manufacturing facility built in Newcastle
Fierce Pharma
NOVEMBER 4, 2024
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar Therapeutics is extending its cash runway with the sale of one of its two mai | Nektar is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity firm Ampersand for a total value of $90 million.
pharmaphorum
NOVEMBER 4, 2024
NHS England starts pilot trial of an iPhone app and device that could be used by nurses to speed up reviews of suspected throat cancer cases.
Fierce Pharma
NOVEMBER 4, 2024
While Eli Lilly and Novo Nordisk had market cap declines in the third quarter, Bristol Myers Squibb, Gilead Sciences and Sanofi saw their value increase, according to GlobalData.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
NOVEMBER 4, 2024
US district court grants an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata
MedCity News
NOVEMBER 4, 2024
The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals. The post Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs appeared first on MedCity News.
Pharmaceutical Technology
NOVEMBER 4, 2024
Researchers from Northwestern and Case Western Reserve universities have developed a polymer therapeutic to treat Huntington's disease.
MedCity News
NOVEMBER 4, 2024
There are some areas where point solutions make a lot of sense, such as when they’re focused on a condition without a lot of comorbidities, according to one healthcare expert. The post Is There Still a Place for Point Solutions? One Investor Weighs In appeared first on MedCity News.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
NOVEMBER 4, 2024
The US FDA has granted fast track designation to FELIQS’ lead product FLQ-101 for preventing retinopathy of prematurity (ROP).
MedCity News
NOVEMBER 4, 2024
Higher doses of a Viking Therapeutics pill that targets two receptors led to greater weight loss without worsening safety or tolerability, according to Phase 1 results presented during the ObesityWeek conference. Meanwhile, an injectable version of this Viking drug is on track to Phase 3 testing. The post Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug appeared first on MedCity News.
PharmaVoice
NOVEMBER 4, 2024
Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.
MedCity News
NOVEMBER 4, 2024
Nutrition isn’t a supplement — it’s foundational to metabolic health. It’s time we integrate more ‘Food as Medicine’ initiatives alongside the GLP-1 therapies that are gaining traction. The post A Recipe for Better Obesity Care: Integrating GLP-1s with Food as Medicine appeared first on MedCity News.
Pharmacy Times
NOVEMBER 4, 2024
Compared with a short-acting β agonist (SABA) alone, inhaled corticosteroids (ICS) with formoteral and ICS with a SABA were associated with better asthma control.
PharmaTech
NOVEMBER 4, 2024
Webinar Date/Time: Tuesday, November 19 2024 at 11: 00 AM EST | 5:00 PM CET
Pharmaceutical Technology
NOVEMBER 4, 2024
Increasingly, injectable manufacturers recognise that to achieve maximum profitability, they need to focus on the value they provide.
PharmaTech
NOVEMBER 4, 2024
This technical brief will cover the use of polymers in a variety of dosage forms (buccal/sublingual tablets, liquid, semi-solid formulations, and oral care products) to impart mucoadhesion. The basic mechanism of mucoadhesion and methods to evaluate it in the context of pharmaceutical applications will also be reviewed, also how it can improve and differentiate drug products.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Technology
NOVEMBER 4, 2024
In an end-of-Phase II meeting, the FDA indicated support for accelerated approval based on existing clinical data.
PharmaTech
NOVEMBER 4, 2024
Carbopol® polymers are efficient suspending agents that simplify manufacturing and improve the dosing experience for pediatric and geriatric patients. They offer excellent performance and versatility as pharmaceutical suspending agents for oral liquid formulations. They are compatible with various APIs, flavors, and preservatives and also provide a reliable supply.
Pharmaceutical Commerce
NOVEMBER 4, 2024
With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.
PharmaTech
NOVEMBER 4, 2024
Looking to improve drug product effectiveness and differentiate? Mucoadhesion – the ability of a formulation to adhere to a mucous membrane – is an attractive option for those keen to ensure their products stand out in a crowded market.
PharmExec
NOVEMBER 4, 2024
Results from the VENTURE Phase II trial and a Phase I oral formulation study found that VK2735, a novel a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.
Pharmaceutical Commerce
NOVEMBER 4, 2024
In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, explains why ultra-precise temperature control and customized logistics solutions are critical when it comes to biologics and personalized medicine.
Pharmaceutical Technology
NOVEMBER 4, 2024
UK-based biopharmaceutical company Prokarium has received two Notices of Allowance from the US Patent and Trademark Office.
Pharmaceutical Commerce
NOVEMBER 4, 2024
The latest news for pharma industry insiders.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
299 
Let's personalize your content